Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis

• Luma Light System (Device): The Luma Light System combines a NBUVB light with an occlusive dressing.
• Luma Light (Device): NBUVB light
• Occlusive Dressing (Device): Off-the-shelf occlusive dressing

Primary outcomes

• Target Plaque Assessment [6 weeks]: Local efficacy will be evaluated with a 0-4 point scale for three signs and symptoms of psoriasis: erythema, plaque elevation, and scaling.
• Local Skin Reactions [6 weeks]: Tolerability will be evaluated through assessment of selected local signs and symptoms at the article-application site: Burning/stinging, pain and pruritus. Each sign or symptom will be graded at Baseline and each subsequent visit using a 0-3 scale (0 = none, 1 = mild, 2 = moderate, or 3 = severe).

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

* Male or female of any race, 18 to 65 (inclusive) years of age.
* Verbal and written informed consent obtained from the subject.
* Has a clinical diagnosis of mild to moderate psoriasis at the Screening and Baseline visits.
* Has an IGA score of 2 or 3.
* Target plaque assessment (TPA) score between 6-9 and a score of at least 2 for each of the 3 different psoriasis signs and symptoms (erythema, plaque elevation, and scaling)
* Has at least 4 plaques of at least 10 cm2 with TPA scores not differing from each other by a score of more than 1
* Is in good general health as determined by the Investigator based on the subject's medical history, vital signs and physical examination.
* Females of childbearing potential must have negative urine pregnancy test results.
* Females of childbearing potential agree to use acceptable methods of contraception from the screening visit continuously until 30 days after end of treatment.
* Subject agrees to use only the Sponsor provided cleanser and lotion during the study period.
* Subject is willing and able to return for all study visits.

Exclusion Criteria:

* Presence of psoriasis that was previously treated with prescription medications prior to the Screening visit and was non-responsive to treatment, as determined by the Investigator.
* Presence of any concurrent skin condition that could interfere with the evaluation of the study device, as determined by the Investigator.
* Female who is pregnant, nursing an infant, or planning a pregnancy during the study period.
* Treatment with any investigational drug or device within 30 days or 5 half-lives (whichever is longer) prior to the Baseline visit, or concurrent participation in another clinical trial with an investigational drug or device.
* History of melanoma.
* Subject has any medical, social or psychological conditions that, in the opinion of the Investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.